{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:03:31Z","timestamp":1790298211661,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.urolonc.2026.08.012","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:49:14Z","timestamp":1790297354000},"page":"931-938","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lymphovascular invasion and nodal positivity may identify candidates for adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8758-776X","authenticated-orcid":false,"given":"Hiroki","family":"Shimoda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Numao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Oki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Urasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Tamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4321-6074","authenticated-orcid":false,"given":"Kosuke","family":"Takemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6566-1430","authenticated-orcid":false,"given":"Ryo","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Yonese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2026.08.012_bib0001","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant Nivolumab versus Placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.08.012_bib0002","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.24.00340","article-title":"Adjuvant Nivolumab in high-risk muscle-invasive urothelial carcinoma: expanded efficacy from CheckMate 274","volume":"43","author":"Galsky","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.08.012_bib0003","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.annonc.2025.09.139","article-title":"Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274","volume":"37","author":"Galsky","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2026.08.012_bib0004","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.14427","article-title":"Clinical outcomes in patients with muscle-invasive urothelial carcinoma treated with Nivolumab","volume":"8","author":"Barrag\u00e1n-Carrillo","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.urolonc.2026.08.012_bib0005","doi-asserted-by":"crossref","first-page":"697.e11","DOI":"10.1016\/j.urolonc.2025.07.014","article-title":"Efficacy of adjuvant nivolumab in patients with upper tract predominant urothelial carcinoma: a single-center real-world study","volume":"43","author":"Chen","year":"2025","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.08.012_bib0006","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s10147-024-02619-8","article-title":"Efficacy and safety of adjuvant nivolumab after radical surgery for high-risk urothelial carcinoma: a preliminary report of real-world data from a single institution","volume":"29","author":"Yasuda","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.08.012_bib0007","article-title":"Real-world evaluation of nivolumab utilization in adjuvant treatment of localized muscle-invasive urothelial carcinoma","volume":"34","author":"Guilbert","year":"2024","journal-title":"Fr J Urol"},{"key":"10.1016\/j.urolonc.2026.08.012_bib0008","article-title":"Adjuvant nivolumab therapy for upper tract urothelial carcinoma: a single-institution study","volume":"17","author":"Minato","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.urolonc.2026.08.012_bib0009","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3390\/cancers15030566","article-title":"Current and future landscape of perioperative treatment for muscle-invasive bladder cancer","volume":"15","author":"Esteban-Villarrubia","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.urolonc.2026.08.012_bib0010","doi-asserted-by":"crossref","first-page":"6533","DOI":"10.1200\/JCO.2005.05.516","article-title":"Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy","volume":"23","author":"Lotan","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.08.012_bib0011","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1111\/j.1464-410X.2008.07732.x","article-title":"The presence of lymphovascular invasion in radical cystectomy specimens from patients with urothelial carcinoma portends a poor clinical prognosis","volume":"102","author":"Canter","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2026.08.012_bib0012","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1464-410X.2009.09166.x","article-title":"Lymphovascular invasion is an independent predictor of oncological outcomes in patients with lymph node-negative urothelial bladder cancer treated by radical cystectomy: a multicentre validation trial","volume":"106","author":"Bolenz","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2026.08.012_bib0013","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1200\/JCO.2008.17.2361","article-title":"Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma","volume":"27","author":"Kikuchi","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.08.012_bib0014","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/j.1464-410X.2011.10893.x","article-title":"Prognostic indicators for upper tract urothelial carcinoma after radical nephroureterectomy: the impact of lymphovascular invasion","volume":"110","author":"Godfrey","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2026.08.012_bib0015","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/bju.12116","article-title":"Impact of lymphovascular invasion on oncological outcomes in patients with upper tract urothelial carcinoma after radical nephroureterectomy","volume":"111","author":"Hurel","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2026.08.012_bib0016","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.08.012_bib0017","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S0959-8049(99)00012-X","article-title":"Prognostic factors in urothelial renal pelvis and ureter tumours: a multicentre Rare Cancer Network study","volume":"35","author":"Ozsahin","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2026.08.012_bib0018","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.08.012_bib0019","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1056\/NEJMoa2511674","article-title":"Perioperative enfortumab Vedotin and Pembrolizumab in bladder cancer","volume":"394","author":"Vulsteke","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.08.012_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102082","article-title":"Site-specific differences of eligibility for adjuvant immunotherapy among urothelial carcinoma patients treated with radical surgery: results from a multicenter cohort study","volume":"22","author":"Narita","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2026.08.012_bib0021","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10147-023-02424-9","article-title":"Real-world outcomes of adjuvant immunotherapy candidates with upper tract urothelial carcinoma: results of a multicenter cohort study","volume":"29","author":"Kagawa","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.08.012_bib0022","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.3390\/jcm13185466","article-title":"Stratifying the risk of disease progression among surgically treated muscle-invasive bladder cancer eligible for adjuvant nivolumab","volume":"13","author":"Flammia","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.urolonc.2026.08.012_bib0023","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/bco2.117","article-title":"Prognostic impact of eligibility for adjuvant immunotherapy in locally advanced urothelial cancer","volume":"3","author":"Miura","year":"2021","journal-title":"BJUI Compass"},{"key":"10.1016\/j.urolonc.2026.08.012_bib0024","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.eururo.2023.06.007","article-title":"Updated overall survival by circulating tumor DNA status from the phase 3 IMvigor010 trial: adjuvant Atezolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"85","author":"Powles","year":"2024","journal-title":"Eur Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926007088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926007088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:49:17Z","timestamp":1790297357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926007088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1078143926007088"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.08.012","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lymphovascular invasion and nodal positivity may identify candidates for adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}